诺诚健华上半年收入增长55.5%并扭亏，但未形成可追的新预期差

InnoCare Pharma(INCPF), a biopharmaceutical company focused on cancer and autoimmune diseases, reported strong financial results for the first half of 2026, sustained profitability and multiple clinical and regulatory milestones across its pipeline.
Company Profile
China-based InnoCare is focused on developing innovative therapies for cancer and autoimmune diseases.
Its portfolio includes BTK inhibitor orelabrutinib, BCL2 inhibitor mesutoclax, two TYK2 inhibitors, and multiple antibody-drug conjugate (ADC) and molecular glue programs.
H1 2026 Financial Highlights
Revenue increased 55.5% year over year to RMB 1.1 billion from RMB 731.4 million, driven by commercial growth and global business development collaborations.
Drug sales rose 43.2% to RMB 918.1 million from RMB 641.2 million, supported by growth of orelabrutinib and contributions from newly launched tafasitamab and zurletrectinib.
The company reported a profit of RMB 239.7 million, compared with a loss of RMB 35.6 million in the prior-year period.
Research and development investment increased 10.5% to RMB 497.1 million from RMB 449.7 million, reflecting continued global clinical development and investment in ADC and molecular glue platforms.
Cash and related accounts stood at approximately RMB 8.4 billion, compared with RMB 7.7 billion as of June 30, 2025.
Key Regulatory And Pipeline Milestones
InnoCare achieved one NDA approval, with orelabrutinib approved in Australia.The company also received two NDA acceptances for orelabrutinib in primary immune thrombocytopenia and zurletrectinib in pediatric solid tumors.
Two Phase 3 studies met their primary endpoints, including soficitinib (ICP-332) in atopic dermatitis and fadeucravacitinib (ICP-488) in psoriasis.
InnoCare initiated three Phase 3 trials evaluating orelabrutinib in systemic lupus erythematosus, mesutoclax plus orelabrutinib in relapsed/refractory mantle cell lymphoma, and mesutoclax plus azacitidine in newly diagnosed acute myeloid leukemia.
The company also advanced four IND programs, including ICP-538, ICP-054, ICP-B208 and ICP-B381.
Commercial And Hemato-Oncology Progress
All four approved indications of orelabrutinib were included in China's updated National Reimbursement Drug List, supporting continued commercial growth.
Tafasitamab and zurletrectinib also began contributing to sales following their launches.
The company continued advancing its hemato-oncology franchise through orelabrutinib, tafasitamab and mesutoclax.
Global development of mesutoclax in AML and myelodysplastic syndrome is progressing across China, the U.S. and Australia, while multiple studies evaluating the therapy in CLL/SLL, mantle cell lymphoma and marginal zone lymphoma continue.
Autoimmune Pipeline Progress
InnoCare is expanding orelabrutinib beyond oncology, with its NDA for primary immune thrombocytopenia accepted in China and a registrational Phase 3 study in systemic lupus erythematosus underway.
Two global Phase 3 studies of orelabrutinib in primary progressive and secondary progressive multiple sclerosis are also ongoing.
Soficitinib achieved its primary endpoint in a Phase 3 atopic dermatitis trial and showed significant improvements in a Phase 2 study in non-segmental vitiligo.
Fadeucravacitinib met its primary and multiple secondary endpoints in a Phase 3 psoriasis study.
Additional autoimmune programs, including ICP-054, ICP-538 and the CD20xCD3 T-cell engager ICP-B02, also continued to advance.
Solid Tumor Pipeline
Zurletrectinib received priority review and NDA acceptance in China for pediatric patients with NTRK fusion-positive solid tumors.
The B7-H3-targeted ADC ICP-B794 began patient enrollment, while the CDH17-targeted ADC ICP-B208 entered clinical development.
InnoCare's PSMA- and STEAP1-targeting bispecific ADC ICP-B381 had its IND application accepted in China, with plans for a U.S. IND submission.
Global Expansion
During the first half of 2026, InnoCare continued expanding internationally, with orelabrutinib receiving approvals in Singapore and Australia.
Going forward, the company plans to pursue further global growth through out-licensing, regional collaborations, in-house development and continued investment in its oncology and autoimmune pipeline.
On August 21, InnoCare's stock closed trading at $1.55 without any movement on the OTC Markets.
For comments and feedback contact: editorial@rttnews.com
Business News
August 21, 2026 14:42 ET The minutes of the latest policy meeting of the Federal Reserve, housing market data and manufacturing sector survey results were the main news for the U.S. economy this week. In Europe, inflation data from the U.K. was the highlight, while consumer price data from Japan drew attention in Asia.